This summer, a drug whose biological target was nominated by one AI system and whose chemical structure was drafted by another entered Phase III. Insilico Medicine's rentosertib, an oral TNIK inhibitor for idiopathic pulmonary fibrosis, is being tested in a trial planned to enroll up to 320 patients at 47 sites in China over 52 weeks. If it completes Phase III, it would be the first drug originated largely by generative AI to complete that stage of clinical testing.
LINKS
Read “Where's the Human? Bio-AI and the Law's Missing Person,” authored by John E. Wehrli, published by the Daily Journal. (subscription)